Immuno-Oncology Industry 2018 Global Pipeline Review Analysis and Outlook 2022

Immuno-Oncology Industry
WiseGuyReports.Com Publish a New Market Research Report On –“ Immuno-Oncology Industry 2018 Global Pipeline Review Analysis and Outlook 2022”.

Description:                                                                                                 

Immuno-oncology is a unique approach that uses the body’s immune system to fight cancer. These therapies activate an individual’s immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022”, the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

 

Get a Sample Report@   https://www.wiseguyreports.com/sample-request/1706519-immuno-oncology-market-by-type-mab-naked-conjugate-cancer-vaccines-immune

For more information or any query mail at sales@wiseguyreports.com

 

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

 

Complete Report Details @   https://www.wiseguyreports.com/reports/1706519-immuno-oncology-market-by-type-mab-naked-conjugate-cancer-vaccines-immune

 

Table Of Contents – Major Key Points

1. Analyst View 

2. Research Methodology 

3. Immuno-Oncology: Overview 

4. Market Dynamic 
4.1 Drivers 
4.1.1 Increasing Cancer Incidences 
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth 
4.1.3 Growing Geriatric Population 
4.1.4 High Healthcare Spending in Developed Economies 
4.1.5 Strong Pipeline 
4.1.6 Increasing Efficacy in a Wide Variety of Indications 
4.1.7 urgeoning Approval and Uptake of Immuno-Oncology Products 
4.2 Challenges 
4.2.1 Patent Expiry of Top-Selling Drugs 
4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment 
4.2.3 Sky-High Development Costs of Cancer Immunotherapies 
4.2.4 High Cost of Treatment 
4.2.5 Lack of Awarenes 
4.3 Opportunities 
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunit 
4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival 
4.3.3 CAR-T Therapies: The Future of Cancer Care 
4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies 

5. Global Immuno-Oncology Market Outlook 2022 

6. Global Immuno-Oncology Market, by Product Class 
6.1 Monoclonal Antibodies (mAbs) 
6.1.1 Naked Monoclonal Antibodies 
6.1.1.1 Rituxan (Rituximab) 
6.1.1.2 Avastin (Bevacizumab) 
6.1.1.3 Herceptin (Trastuzumab) 
6.1.2 Conjugated Monoclonal Antibodies 
6.1.2.1 ADCETRIS (Brentuximab vedotin) 
6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1) 
6.1.3 Bispecific Monoclonal Antibodies 
6.1.3.1 Blincyto (Blinatumomab) 
6.1.4 Others 
6.2 Therapeutic Vaccines 
6.2.1 Provenge 
6.3 Immune Checkpoint Inhibitors 
6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4) 
6.3.1.1 Yervoy (Ipilimumab) 
6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand 
6.3.2.1 Opdivo (Nivolumab) 
6.3.2.2 Keytruda (Pembrolizumab) 
6.4 Others 

7. Global Immuno-Oncology Market, By Major Indications 
7.1 Head & Neck Cancer 
7.2 Lung Cancer 
7.3 Melanoma 
7.4 Lymphoma 
7.5 Leukemia 
7.6 Others 118 

8. Global Immuno-Oncology Market, By Geography 
8.1 North America 
8.2 Europe 
8.3 Asia-Pacific 

9. Trends & Developments 
9.1 Lucrative Investment Trend 
9.2 Emergence of Targeted and Combination Therapies 
9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market 
9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers 

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry 

11. Pipeline Analysis of Immuno-Oncology 

12. Competitive Landscape 
12.1 Share of Major Players 

Continue……

For more information or any query mail at sales@wiseguyreports.com

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com